Publications
Detailed Information
Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Mi Jeong | - |
dc.contributor.author | Ryu, Jai Min | - |
dc.contributor.author | Cho, Soo Youn | - |
dc.contributor.author | Nam, Seok Jin | - |
dc.contributor.author | Kim, Seok Won | - |
dc.contributor.author | Lee, Jeeyeon | - |
dc.contributor.author | Lee, Soo Jung | - |
dc.contributor.author | Park, Ji-Young | - |
dc.contributor.author | Park, Ho Yong | - |
dc.contributor.author | Hong, Sungjun | - |
dc.contributor.author | Kim, Kyunga | - |
dc.contributor.author | Han, Jinil | - |
dc.contributor.author | Moon, Youngho | - |
dc.contributor.author | Shin, Young Kee | - |
dc.contributor.author | Lee, Jeong Eon | - |
dc.date.accessioned | 2023-12-11T00:49:51Z | - |
dc.date.available | 2023-12-11T00:49:51Z | - |
dc.date.created | 2021-04-22 | - |
dc.date.issued | 2021-02-23 | - |
dc.identifier.citation | Frontiers in Oncology, Vol.11, p. 588728 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | https://hdl.handle.net/10371/197807 | - |
dc.description.abstract | Background: The prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group. Methods: We identified patients with pN0-1, HR+/HER2- breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score. Results: A total of 712 patients were eligible for analysis. The median follow-up time was 7.47 years. The BCT score was prognostic in patients aged <= 50 years (n = 404) and those aged >50 years (n = 308). In both age groups, the 10-year DMFS and DFS rates for patients classified as high risk by the BCT score were significantly lower than those for patients classified as low risk. A multivariate analysis revealed that the BCT score was an independent prognostic factor for DFS in patients aged <= 50 years (hazard ratio, 1.28; 95% CI, 1.05-1.56; P = 0.015), as well as those aged >50 years. Conclusion: The BCT score could be used to identify low-risk patients who will not benefit from adjuvant chemotherapy to treat HR+/HER2- early breast cancer regardless of age. A further prospective study to assess the prognostic and predictive value of the BCT score is required. | - |
dc.language | 영어 | - |
dc.publisher | Frontiers Media S.A. | - |
dc.title | Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fonc.2021.588728 | - |
dc.citation.journaltitle | Frontiers in Oncology | - |
dc.identifier.wosid | 000626633900001 | - |
dc.identifier.scopusid | 2-s2.0-85102344686 | - |
dc.citation.startpage | 588728 | - |
dc.citation.volume | 11 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Shin, Young Kee | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | GenesWell BCT assay | - |
dc.subject.keywordAuthor | BCT score | - |
dc.subject.keywordAuthor | prognostic value | - |
dc.subject.keywordAuthor | predictive value | - |
dc.subject.keywordAuthor | young breast cancer patients | - |
dc.subject.keywordAuthor | HR+/HER2-early breast cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.